Compare Herbalife Nutrition Ltd (HLF) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Smith & Nephew plc — how do they compare? Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 10.2× Herbalife Nutrition Ltd's market cap, and Smith & Nephew plc pays a 2.65% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.
| HLF | SNN | |
|---|---|---|
Market Cap | $1.23B | $12.54B |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $38.70 |
52-Week Low | $7.75 | $28.73 |
Enterprise Value | $3.06B | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $11.695, up 1.52% on the day, with a bearish technical outlook per moving averages. The company reported Q2 2026 net sales of $1.3 billion, a 5.4% year-over-year increase, though EPS of $0.51 missed estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24. Positive news includes being named to TIME's America's Best Companies 2026 list, but a planned CFO transition in December 2026 introduces uncertainty.
The outlook is mixed; strong sales growth and low valuation metrics offer potential upside, but recent earnings misses, a high debt load, and negative shareholder equity pose significant risks. Analyst consensus leans bullish with 53.84% buy ratings, yet the stock faces headwinds from competitive pressures and margin volatility.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
